What we do
Personalized and Precision Medicine can transform lives, but its potential benefits have not yet been fully realized.
Why is that? Because:
As a result, patients do not benefit from optimal treatment, with a health, societal and economic impact.
The From Testing to Targeted Treatments program (FT3) aims to respond to these challenges, through a co-creation approach, building with patients for patients.
Accelerate the benefits of precision medicine by generating better evidence, creating awareness and building the conditions for better access to targeted medicine in oncology and beyond.
A global catalyst identifying and sharing translatable good practices & learnings
FT3 brings together diverse stakeholders and activities in precision medicine to identify shared needs, build on existing good practices and learnings and make them replicable through practical and actionable tools and resources for precision medicine champions to drive real change and impact, starting with cancer and testing.
Identify common needs & opportunities
Identify learnings and good practices, building on them & making them replicable
Where good practices don’t exist, co-create new solutions, drawing on existing knowledge
Create positive momentum & building on active community of practice to collaborate, share and test
Starting with practical resources & support for precision medicine champions to accelerate precision medicine in different contexts
Members have identified 3 key strategic pillars:
To make precision medicine an accessible reality for all patients who could benefit from it
Support data & evidence development
to demonstrate benefits of precision medicine on patient outcomes and put in place a data governance structure
Provide education and tools
to support patient empowerment and informed decision-making
Build the accessibility conditions for precision medicine
to become a reality for patients that would benefit it
Keep up to date with the latest developments from the FT3 Program
We don’t spam. Just key info at the right time.